Von Hoff DD - Search Results

1

Inhibiting stromal Class I HDACs curbs pancreatic cancer progression.

Liang G, Oh TG, Hah N, Tiriac H, Shi Y, Truitt ML, Antal CE, Atkins AR, Li Y, Fraser C, Ng S, Pinto AFM, Nelson DC, Estepa G, Bashi S, Banayo E, Dai Y, Liddle C, Yu RT, Hunter T, Engle DD, Han H, Von Hoff DD, Downes M, Evans RM. Liang G, et al. Among authors: von hoff dd. Nat Commun. 2023 Dec 6;14(1):7791. doi: 10.1038/s41467-023-42178-6. Nat Commun. 2023. PMID: 38057326 Free PMC article.

2

Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.

Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Han H, et al. Among authors: von hoff dd. Cancer Res. 2002 May 15;62(10):2890-6. Cancer Res. 2002. PMID: 12019169

3

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer.

Rojanala S, Han H, Muñoz RM, Browne W, Nagle R, Von Hoff DD, Bearss DJ. Rojanala S, et al. Among authors: von hoff dd. Mol Cancer Ther. 2004 Apr;3(4):451-7. Mol Cancer Ther. 2004. PMID: 15078988

4

PRL phosphatases as potential molecular targets in cancer.

Stephens BJ, Han H, Gokhale V, Von Hoff DD. Stephens BJ, et al. Among authors: von hoff dd. Mol Cancer Ther. 2005 Nov;4(11):1653-61. doi: 10.1158/1535-7163.MCT-05-0248. Mol Cancer Ther. 2005. PMID: 16275986 Review.

5

Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents.

Wang H, Han H, Mousses S, Von Hoff DD. Wang H, et al. Among authors: von hoff dd. Semin Oncol. 2006 Aug;33(4):513-20. doi: 10.1053/j.seminoncol.2006.04.013. Semin Oncol. 2006. PMID: 16890805 Review.

6

Aurora sheds light on head and neck squamous cell carcinoma.

Han H, Von Hoff DD. Han H, et al. Among authors: von hoff dd. Clin Cancer Res. 2006 Sep 1;12(17):5003-4. doi: 10.1158/1078-0432.CCR-06-1329. Clin Cancer Res. 2006. PMID: 16951211 Review. No abstract available.

7

Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.

Wang H, Han H, Von Hoff DD. Wang H, et al. Among authors: von hoff dd. Cancer Res. 2006 Oct 1;66(19):9722-30. doi: 10.1158/0008-5472.CAN-05-4602. Cancer Res. 2006. PMID: 17018631

8

Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells.

Wang H, Stephens B, Von Hoff DD, Han H. Wang H, et al. Among authors: von hoff dd. Pancreas. 2009 Jul;38(5):551-7. doi: 10.1097/MPA.0b013e31819d7415. Pancreas. 2009. PMID: 19276868

9

Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.

Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H. Diep CH, et al. Among authors: von hoff dd. Clin Cancer Res. 2011 May 1;17(9):2744-56. doi: 10.1158/1078-0432.CCR-10-2214. Epub 2011 Mar 8. Clin Cancer Res. 2011. PMID: 21385921 Free PMC article.

10

Perineural invasion and associated pain in pancreatic cancer.

Bapat AA, Hostetter G, Von Hoff DD, Han H. Bapat AA, et al. Among authors: von hoff dd. Nat Rev Cancer. 2011 Sep 23;11(10):695-707. doi: 10.1038/nrc3131. Nat Rev Cancer. 2011. PMID: 21941281 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

672 results

Search Page